Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities

被引：139

作者：

McNerney, Ruth ^{[2
]}

Maeurer, Markus ^{[3
,4
,5
]}

Abubakar, Ibrahim ^{[6
,7
]}

Marais, Ben ^{[8
,9
]}

Mchugh, Timothy D.

Ford, Nathan ^{[10
]}

Weyer, Karin ^{[11
]}

Lawn, Steve ^{[12
]}

Grobusch, Martin P. ^{[13
]}

Memish, Ziad ^{[14
,15
]}

Squire, S. Bertel ^{[16
]}

Pantaleo, Giuseppe ^{[17
,18
]}

Chakaya, Jeremiah ^{[19
,20
]}

Casenghi, Martina ^{[10
]}

Migliori, Giovanni-Batista ^{[21
]}

Mwaba, Peter ^{[22
,23
]}

Zijenah, Lynn ^{[24
]}

Hoelscher, Michael ^{[25
]}

Cox, Helen ^{[10
,26
]}

Swaminathan, Soumya ^{[27
]}

Kim, Peter S. ^{[28
]}

Schito, Marco ^{[29
,30
]}

Harari, Alexandre ^{[17
,18
,31
]}

Bates, Matthew ^{[17
,18
,31
]}

Schwank, Samana ^{[23
]}

O'Grady, Justin ^{[23
]}

Pletschette, Michel ^{[32
,33
]}

Ditui, Lucica ^{[34
]}

Atun, Rifat ^{[35
,36
]}

Zumla, Alimuddin ^{[1
,23
]}

机构：

[1] Royal Free Hosp, Ctr Clin Microbiol, Div Infect & Immun, Univ Coll London Med Sch, London NW3 2PF, England

[2] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Pathogen Mol Biol, London, England

[3] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden

[4] Karolinska Inst, Ctr Allogene Stem Cell Transplantat, Stockholm, Sweden

[5] Karolinska Inst, Dept Lab Med, Stockholm, Sweden

[6] Hlth Protect Agcy, TB Sect, Hlth Protect Serv, London, England

[7] Univ E Anglia, Norwich Med Sch, Norwich NR4 7TJ, Norfolk, England

[8] Univ Sydney, Sydney Emerging Infect Dis & Biosecur Inst, Sydney, NSW 2006, Australia

[9] Univ Sydney, Sydney Med Sch, Childrens Hosp Westmead, Sydney, NSW 2006, Australia

[10] Med Sans Frontieres, S Africa Unit, Cape Town, South Africa

[11] WHO, TB Diagnost & Lab Strengthening, Stop TB Dept, CH-1211 Geneva, Switzerland

[12] Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7700 Rondebosch, South Africa

[13] Univ Amsterdam, Acad Med Ctr, Div Internal Med, Dept Infect Dis, NL-1105 AZ Amsterdam, Netherlands

[14] Alfaisal Univ, Minist Hlth, Riyadh, Saudi Arabia

[15] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia

[16] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England

[17] Univ Lausanne, CHU Vaudois, Swiss Vaccine Res Inst, CH-1015 Lausanne, Switzerland

[18] Univ Lausanne, CHU Vaudois, Div Immunol & Allergy, CH-1015 Lausanne, Switzerland

[19] Kenya Govt Med Res Ctr, Ctr Resp Dis Res, Nairobi, Kenya

[20] Minist Hlth, Natl TB Programme, Nairobi, Kenya

[21] Fdn S Maugeri, Care & Res Inst, WHO Collaborating Ctr TB & Lung Dis, Tradate, Italy

[22] Minist Hlth, Lusaka, Zambia

[23] UNZA UCLMS Project, Lusaka, Zambia

[24] Univ Zimbabwe, Coll Hlth Sci, Dept Immunol, Harare, Zimbabwe

[25] Univ Munich, Dept Infect Dis & Trop Med, D-80539 Munich, Germany

[26] Monash Univ, Melbourne, Vic 3004, Australia

[27] Natl Inst Res TB, Madras, Tamil Nadu, India

[28] NIAID, TB Team, Div Acquired Immunodeficiency Syndrome, NIH, Bethesda, MD 20892 USA

[29] NIAID, Vaccine Clin Res Branch, Div Acquired Immunodeficiency Syndrome, NIH, Bethesda, MD 20892 USA

[30] Henry M Jackson Fdn Adv Mil Med, Bethesda, MD USA

[31] Univ Lausanne, CHU Vaudois, Swiss Vaccine Res Inst, CH-1015 Lausanne, Switzerland

[32] European Commiss Brussels, Unit Evaluat, Brussels, Belgium

[33] European Commiss Brussels, Audit Directorate Publ Hlth, Brussels, Belgium

[34] WHO, STOP TB Partnership, CH-1211 Geneva, Switzerland

[35] Global Fund, Geneva, Switzerland

[36] Univ London Imperial Coll Sci Technol & Med, London, England

来源：

JOURNAL OF INFECTIOUS DISEASES | 2012年 / 205卷

基金：

英国医学研究理事会;

关键词：

XPERT MTB/RIF TEST; GAMMA RELEASE ASSAYS; T-CELL RESPONSES; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; INTRATHORACIC TUBERCULOSIS; RESISTANT TUBERCULOSIS; ACTIVE TUBERCULOSIS; ASPIRATION BIOPSY; CHILDREN;

D O I：

10.1093/infdis/jir860

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Tuberculosis is unique among the major infectious diseases in that it lacks accurate rapid point-of-care diagnostic tests. Failure to control the spread of tuberculosis is largely due to our inability to detect and treat all infectious cases of pulmonary tuberculosis in a timely fashion, allowing continued Mycobacterium tuberculosis transmission within communities. Currently recommended gold-standard diagnostic tests for tuberculosis are laboratory based, and multiple investigations may be necessary over a period of weeks or months before a diagnosis is made. Several new diagnostic tests have recently become available for detecting active tuberculosis disease, screening for latent M. tuberculosis infection, and identifying drug-resistant strains of M. tuberculosis. However, progress toward a robust point-of-care test has been limited, and novel biomarker discovery remains challenging. In the absence of effective prevention strategies, high rates of early case detection and subsequent cure are required for global tuberculosis control. Early case detection is dependent on test accuracy, accessibility, cost, and complexity, but also depends on the political will and funder investment to deliver optimal, sustainable care to those worst affected by the tuberculosis and human immunodeficiency virus epidemics. This review highlights unanswered questions, challenges, recent advances, unresolved operational and technical issues, needs, and opportunities related to tuberculosis diagnostics.

引用

页码：S147 / S158

页数：12

共 94 条

[1]

[Anonymous], 9 M WHO STRAT TECHN

[2]

[Anonymous], 2011, PERF XPERT MTB RIF V

[3]

[Anonymous], NICE CLIN GUID

[4]

[Anonymous], US INT GAMM REL ASS

[5]

[Anonymous], 2010, WORLD HLTH STAT 2010

[6]

[Anonymous], 2010, Multidrug and extensively drug-resistant TB(M/XDR-TB): 2010 Global Report on Surveillance and Response

[7]

[Anonymous], 2008, NEW LAB DIAGN TOOLS

[8]

[Anonymous], 2009 REP TUB RES FUN

[9]

[Anonymous], LANCET INFECT DIS, DOI DOI 10.1016/S0140-6736(10)62173-3

[10]

[Anonymous], BIOMARKERS, DOI DOI 10.1073/pnas.1009080107

← 1 2 3 4 5 6 7 8 9 10 →